靶向促肾上腺皮质激素细胞HDAC与PI3K治疗库欣病
该研究通过高通量筛选发现双重PI3K/HDAC抑制剂CUDC-907可抑制鼠源和人源促肾上腺皮质激素肿瘤的ACTH分泌与细胞增殖。在鼠异种移植模型中,口服CUDC-907(300 mg/kg)使肿瘤体积缩小65%,并分别降低血浆ACTH和皮质酮水平77%和85%。CUDC-907通过抑制HDAC1/2在POMC转录水平及PI3K介导的细胞活力抑制发挥作用,可能成为库欣病的有前景疗法。
要点
- 口服CUDC-907(300 mg/kg)使鼠移植瘤体积缩小65%,血ACTH降77%,皮质酮降85%。
- CUDC-907通过HDAC1/2抑制POMC转录及PI3K抑制细胞活力降低ACTH分泌。
核心结论
- CUDC-907在库欣病体外和体内模型中均显示强效,结合临床试验中已证明的安全性和耐受性,可能成为库欣病的有前景疗法。
研究设计与样本
- 采用新型「信号增益」ACTH AlphaLISA assay进行高通量筛选,使用库欣病患者促肾上腺皮质激素肿瘤组织及鼠源肿瘤模型。
主要发现
- 从激酶抑制剂库中鉴定出双重PI3K/HDAC抑制剂CUDC-907,抑制鼠源和人源促肾上腺皮质激素肿瘤ACTH分泌(中位有效浓度1-5 nM)和细胞增殖(中位抑制浓度5 nM)。
- 在鼠促肾上腺皮质激素肿瘤异种移植模型中,口服CUDC-907(300 mg/kg)使肿瘤体积(TV [cm3])从对照0.17 ± 0.05降至0.07 ± 0.02(P < .05),缩小65%。
- 同一模型中,CUDC-907使血浆ACTH(pg/mL)从对照206 ± 27降至47 ± 7(P < .05),降低77%;皮质酮(ng/mL)从对照180 ± 87降至27 ± 5(P < .05),降低85%。
- CUDC-907通过抑制HDAC1/2在POMC转录水平及通过PI3K介导抑制促肾上腺皮质激素细胞活力,减少ACTH分泌。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Cushing disease (CD) is a life-threatening disorder. Therapeutic goals include symptom relief, biochemical control, and tumor growth inhibition. Current medical therapies for CD by and large exert no action on tumor growth. OBJECTIVE: To identify drugs that inhibit corticotroph tumor adrenocorticotropic hormone (ACTH) secretion and growth. DESIGN: High throughput screen employing a novel "gain of signal" ACTH AlphaLISA assay. SETTING: Academic medical center. PATIENTS: Corticotroph tumor tissues from patients with CD. INTERVENTIONS: None. MAIN OUTCOME MEASURES: Potent inhibitors of corticotroph tumor ACTH secretion and growth. RESULTS: From a kinase inhibitor library, we identified the dual PI3K/HDAC inhibitor CUDC-907 as a potent inhibitor of murine and human corticotroph tumor ACTH secretion (median effective concentration 1-5 nM), and cell proliferation (median inhibitory concentration 5 nM). In an in vivo murine corticotroph tumor xenograft model, orally administered CUDC-907 (300 mg/kg) reduced corticotroph tumor volume (TV [cm3], control 0.17 ± 0.05 vs CUDC-907 0.07 ± 0.02, P < .05) by 65% and suppressed plasma ACTH (ACTH [pg/mL] control 206 ± 27 vs CUDC-907 47 ± 7, P < .05) and corticosterone (corticosterone [ng/mL] control 180 ± 87 vs CUDC-907 27 ± 5, P < .05) levels by 77% and 85% respectively compared with controls. We also demonstrated that CUDC-907 acts through HDAC1/2 inhibition at the proopiomelanocortin transcriptional level combined with its PI3K-mediated inhibition of corticotroph cell viability to reduce ACTH secretion. CONCLUSIONS: Given its potent efficacy in in vitro and in vivo models of CD, combined with proven safety and tolerance in clinical trials, we propose CUDC-907 may be a promising therapy for CD.
引用
- Zhang D, Damoiseaux R, Babayan L, et al. Targeting Corticotroph HDAC and PI3-Kinase in Cushing Disease. J Clin Endocrinol Metab. 2021. PMID: 33000123. doi:10.1210/clinem/dgaa699
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。